Charles Dadswell - Illumina Senior Vice President General Counsel, Secretary
| ILMN Stock | USD 85.68 0.08 0.09% |
President
Mr. Charles E. Dadswell is the Senior Vice President, General Counsel, Secretary of Illumina Inc. since April 22, 2013. Mr. Dadswell joins Illumina with more than 20 years of leadership and legal experience at health carefocused technology companies. Most recently, he was Vice President, General Counsel for North and Latin America and Corporationrationrate Director of Global Intellectual Property at bioMerieux. In this role, he was responsible for a global intellectual property matters and legal matters in North and Latin America. Prior to bioMerieux, he was General Counsel of BioDelivery Sciences International, a specialty pharmaceutical company and oversaw US intellectual property in a variety of positions with Glaxo, GlaxoWellcome and GlaxoSmithKline since 2013.
| Age | 65 |
| Tenure | 12 years |
| Phone | 858 202 4500 |
| Web | https://www.illumina.com |
Illumina Management Efficiency
The company has return on total asset (ROA) of 0.0264 % which means that it generated a profit of $0.0264 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3013) %, meaning that it created substantial loss on money invested by shareholders. Illumina's management efficiency ratios could be used to measure how well Illumina manages its routine affairs as well as how well it operates its assets and liabilities.Illumina currently holds 2.54 B in liabilities with Debt to Equity (D/E) ratio of 0.38, which is about average as compared to similar companies. Illumina has a current ratio of 0.91, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Illumina's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Rodney Gonsalves | Agilent Technologies | 59 | |
| Robert McMahon | Agilent Technologies | 55 | |
| Jacob Thaysen | Agilent Technologies | 49 | |
| Patrick Finn | Twist Bioscience Corp | 53 | |
| William King | Danaher | 53 | |
| Dominique Grau | Agilent Technologies | 66 | |
| Elizabeth Rae | Waters | 60 | |
| John Lynch | Waters | N/A | |
| Stephen Williamson | Thermo Fisher Scientific | 58 | |
| Paula Green | Twist Bioscience Corp | 57 | |
| Michael Tang | Agilent Technologies | 50 | |
| Daniel Raskas | Danaher | 54 | |
| Brian Ellis | Danaher | 57 | |
| Mark Stevenson | Thermo Fisher Scientific | 57 | |
| Matthew McGrew | Danaher | 53 | |
| Angelica III | Agilent Technologies | N/A | |
| Amol Chaubal | Waters | 48 | |
| Michael Boxer | Thermo Fisher Scientific | 58 | |
| Robert Lutz | Danaher | 62 | |
| Henrik AncherJensen | Agilent Technologies | 60 | |
| Sharon Underberg | IDEXX Laboratories | 63 | |
Management Performance
| Return On Equity | -0.3 | ||||
| Return On Asset | 0.0264 |
Illumina Leadership Team
Elected by the shareholders, the Illumina's board of directors comprises two types of representatives: Illumina inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Illumina. The board's role is to monitor Illumina's management team and ensure that shareholders' interests are well served. Illumina's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Illumina's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Hoffman, Segment Sequencing | ||
| Francis deSouza, Pres and Director | ||
| Jacob Thaysen, CEO Director | ||
| Pat Leckman, Interim Officer | ||
| Charles Dadswell, Senior Vice President General Counsel, Secretary | ||
| Ankur Dhingra, Chief Officer | ||
| Nicole Berry, Head RegionAmericas | ||
| Mena Farag, Senior Specialist | ||
| Scott Ericksen, VP Officer | ||
| Kevin Pegels, Chief Operations | ||
| Charles Esq, Senior Counsel | ||
| Joydeep MBA, Executive Officer | ||
| Sharon Vidal, Global Responsibility | ||
| Jakob Wedel, Chief Staff | ||
| Bas Verhoef, Interim RegionEurope | ||
| Sallilyn Schwartz, Vice Relations | ||
| Susan Tousi, Chief Officer | ||
| Kathryne Reeves, Chief Officer | ||
| Scott Davies, Interim Secretary | ||
| Ankur CPA, Chief Officer | ||
| Steven Barnard, Chief Officer | ||
| Alexander MD, CTO Devel | ||
| Stephanie Campos, President | ||
| Carissa Rollins, Chief Officer | ||
| Jenny Zheng, Head China | ||
| Gretchen Weightman, Middle Pacific |
Illumina Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Illumina a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.3 | ||||
| Return On Asset | 0.0264 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.1) % | ||||
| Current Valuation | 14.96 B | ||||
| Shares Outstanding | 158.4 M | ||||
| Shares Owned By Insiders | 0.30 % | ||||
| Shares Owned By Institutions | 99.70 % | ||||
| Number Of Shares Shorted | 6.44 M | ||||
| Price To Earning | 49.12 X |
Pair Trading with Illumina
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Illumina position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Illumina will appreciate offsetting losses from the drop in the long position's value.Moving together with Illumina Stock
Moving against Illumina Stock
| 0.88 | VALN | Valneva SE ADR Earnings Call Today | PairCorr |
| 0.79 | DVAX | Dynavax Technologies | PairCorr |
| 0.55 | EQ | Equillium | PairCorr |
| 0.5 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.47 | VIGL | Vigil Neuroscience | PairCorr |
The ability to find closely correlated positions to Illumina could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Illumina when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Illumina - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Illumina to buy it.
The correlation of Illumina is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Illumina moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Illumina moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Illumina can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Illumina. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Illumina Stock, please use our How to Invest in Illumina guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Illumina. If investors know Illumina will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Illumina listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Illumina is measured differently than its book value, which is the value of Illumina that is recorded on the company's balance sheet. Investors also form their own opinion of Illumina's value that differs from its market value or its book value, called intrinsic value, which is Illumina's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Illumina's market value can be influenced by many factors that don't directly affect Illumina's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Illumina's value and its price as these two are different measures arrived at by different means. Investors typically determine if Illumina is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Illumina's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.